Anebulo Pharmaceuticals (214) Financial Statements
Anebulo Pharmaceuticals Financial Overview
Anebulo Pharmaceuticals's market cap is currently $8.80M. The company's EPS TTM is $-0.19; its P/E ratio is -1.58; Anebulo Pharmaceuticals is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -9.22M | $ -8.31M | $ -11.78M | $ -6.83M | $ -3.61M |
| EBITDA | $ -7.72M | $ -7.90M | $ -11.73M | $ -6.83M | $ -30.24M |
| Net Income | $ -8.48M | $ -8.20M | $ -11.73M | $ -6.83M | $ -30.25M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 11.63M | $ 3.09M | $ 11.25M | $ 14.55M | $ 19.99M |
| Total Assets | $ 12.15M | $ 4.07M | $ 11.67M | $ 15.58M | $ 21.65M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -11.63M | $ -3.09M | $ -11.25M | $ -14.55M | $ -19.99M |
| Total Liabilities | $ 487.69K | $ 260.58K | $ 1.07M | $ 512.53K | $ 241.63K |
| Stockholders' Equity | $ 11.66M | $ 3.81M | $ 10.60M | $ 15.07M | $ 21.41M |
| Cash Flow | |||||
| Free Cash Flow | $ -6.35M | $ -8.09M | $ -9.68M | $ -5.44M | $ -4.87M |
| Operating Cash Flow | $ -6.35M | $ -8.09M | $ -9.68M | $ -5.44M | $ -4.87M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 14.88M | $ -62.35K | $ 6.38M | $ 0.00 | $ 21.83M |
Currency in USD